Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer

被引：6
|
作者：
Kataoka, Shunichi [1 ]
Matsuno, Kei [1 ]
Sugano, Koji [1 ]
Takahashi, Kazuhisa [2 ]
机构：
[1] Juntendo Tokyo Koto Geriatr Med Ctr, Div Resp Med, Koto Ku, Tokyo, Japan
[2] Juntendo Univ, Sch Med, Grad Sch Med, Bunkyo Ku, Tokyo, Japan
来源：
BMJ CASE REPORTS | 2022年 / 15卷 / 10期
关键词：
Endocrine system; Thyroid disease; Lung cancer (oncology); ASSOCIATION; GUIDELINES; MANAGEMENT;
D O I：
10.1136/bcr-2022-250696
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Thyroid storm is a rare and life-threatening condition associated with excess thyroid hormones. Early detection of thyroid storm is the key to decreasing the morbidity and mortality associated with this condition. We present a rare case of thyroid storm induced by combination therapy with nivolumab and ipilimumab in a patient with advanced non-small cell lung cancer (NSCLC). Because of prominent hyperthyroidism with gastrointestinal symptoms and signs of heart failure, the patient was diagnosed with thyroid storm 3 weeks after initiating this combination immunotherapy. The patient had no history of thyroid disease but was positive for antithyroid antibodies. This case report suggests that thyroid function and symptoms of suspected thyroid storm should be evaluated routinely within 3 weeks from the initiation of therapy when combination therapy is administered in patients with NSCLC positive for antithyroid antibodies.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase I Study of Nivolumab and Ipilimumab Combined with Nintedanib in Advanced Non-Small Cell Lung Cancer
    Puri, S.
    Guadalupe, N. Rodriguez
    Niyongere, S.
    Boyle, T.
    Thapa, R.
    Chen, D.
    Noyes, D.
    Chatwal, M.
    Antonia, S.
    Gray, J. E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S640 - S641
  • [2] Clinical outcome of nivolumab and ipilimumab in untreated advanced non-small cell lung cancer patients
    Sugimoto, Akira
    Kaneda, Hiroyasu
    Nagamine, Hiroaki
    Nakahama, Kenji
    Ogawa, Koichi
    Matsumoto, Yoshiya
    Sawa, Kenji
    Tani, Yoko
    Mitsuoka, Shigeki
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    ANNALS OF ONCOLOGY, 2023, 34 : S1451 - S1451
  • [3] The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer
    Puri, Sonam
    Tanvetyanon, Tawee
    Creelan, Ben C.
    Shafique, Michael Rahman
    Saltos, Andreas Nicholas
    Chiappori, Alberto
    Haura, Eric B.
    Thapa, Ram
    Chen, Dung-Tsa
    Boyle, Theresa A.
    Antonia, Scott Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
    Hellmann, M. D.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S. -W.
    Carcereny Costa, E.
    Park, K.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Peters, S.
    Syrigos, K.
    Barlesi, F.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Rabindran, S. K.
    Kasinathan, R. S.
    Nathan, F. E.
    Ramalingam, S. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2020 - 2031
  • [5] The Impact of Gut Microbiome on the Efficacy of Ipilimumab plus Nivolumab in Advanced Non-Small Cell Lung Cancer
    Katayama, Yuki
    Yamada, Tadaaki
    Sawada, Ryo
    Harada, Taishi
    Chihara, Yusuke
    Yoshimura, Akihiro
    Shiotsu, Shinsuke
    Okada, Asuka
    Yamada, Takahiro
    Takemura, Yoshizumi
    Takayama, Koichi
    CANCER SCIENCE, 2025, 116 : 527 - 527
  • [6] Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma
    Diab, A.
    Abdel-Wahab, N.
    Bentebibel, S. E.
    Montazari, E. J.
    Spillson, C. A.
    Ekmekcioglu, S.
    Gao, J.
    Altan, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1456 - S1456
  • [7] Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non-Small Cell Lung Cancer
    Puri, S.
    Tanvetyanon, T.
    Creelan, B.
    Shafique, M.
    Saltos, A.
    Chiappori, A.
    Haura, E.
    Thapa, R.
    Chen, D.
    Antonia, S.
    Gray, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S924 - S925
  • [8] Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
    Reuss, Joshua E.
    Anagnostou, Valsamo
    Cottrell, Tricia R.
    Smith, Kellie N.
    Verde, Franco
    Zahurak, Marianna
    Lanis, Mara
    Murray, Joseph C.
    Chan, Hok Yee
    McCarthy, Caroline
    Wang, Daphne
    White, James R.
    Yang, Stephen
    Battafarano, Richard
    Broderick, Stephen
    Bush, Errol
    Brock, Malcolm
    Ha, Jinny
    Jones, David
    Merghoub, Taha
    Taube, Janis
    Velculescu, Victor E.
    Rosner, Gary
    Illei, Peter
    Pardoll, Drew M.
    Topalian, Suzanne
    Naidoo, Jarushka
    Levy, Ben
    Hellmann, Matthew
    Brahmer, Julie R.
    Chaft, Jamie E.
    Forde, Patrick M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [9] Combined immunotherapy for non-small cell lung cancer
    Shiraishi, Yoshimasa
    ANNALS OF ONCOLOGY, 2022, 33 : S416 - S416
  • [10] Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Huang, Joy
    Reckamp, Karen L.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 400 - 408
12345